6th November, 2026

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

Scrip Code: BSE - 524500

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

Scrip Code: NSE - KILITCH

Sub: Outcome of the Board Meeting

Dear Sir,

In continuation of our letter dated 2nd November, 2026 and pursuant to Regulation 30 and Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that the Board of Directors of the Company at its meeting held today i.e. Friday, 6th November, 2026 have considered and approved the following;

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026. The copy of Unaudited Financial Results (Standalone and Consolidated) as considered and approved by the Board of Directors along with Limited Review Report by the Auditors are enclosed herewith for your ready reference.

The Board Meeting commenced at 16:30 hours and concluded at 20:30 hours.

Request you to kindly take note of the same and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

MUKUND PRATAPRAI MEHTA
Digitally signed by MUKUND PRATAPRAI MEHTA
Date: 2026.11.06 20:33:15 +05'30'

Mukund Mehta
Managing Director
DIN: 00147876

KILITCH DRUGS (INDIA) LIMITED

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2026

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

		Three Months Ended			Six Months Ended		Year Ended
		30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income**						
	Net Sales/ Income from operations	4,349.26	4,091.20	3,781.35	8,440.46	7,193.55	18,857.43
	Other Income	276.69	354.76	760.89	631.45	1,110.41	1,384.85
	Total Income	**4,625.95**	**4,445.96**	**4,542.24**	**9,071.91**	**8,303.96**	**20,242.28**
2	**Expenses**						
	Cost of Materials Consumed	1,689.79	2,024.54	1,568.37	3,714.33	3,321.80	8,780.36
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(60.08)	(19.81)	206.90	(79.89)	130.81	106.73
	Employee Benefit Expenses	430.75	352.50	328.25	783.25	567.74	1,233.50
	Finance Cost	153.80	48.63	67.86	202.43	126.52	244.31
	Depreciation and Amortisation Expenses	344.43	75.86	52.70	420.30	102.57	228.80
	Export Product Registration/Commission	550.12	519.77	527.11	1,069.89	1,077.61	2,139.01
	Other Expenses	914.89	749.66	783.66	1,664.55	1,371.33	3,354.20
	Total Expenses	**4,023.70**	**3,751.16**	**3,534.85**	**7,774.86**	**6,698.38**	**16,086.91**
3	**Profit / (Loss) before Exceptional items (1-2)**	**602.25**	**694.80**	**1,007.39**	**1,297.05**	**1,605.58**	**4,155.37**
4	Exceptional Items	-	-	-	-	-	
5	**Profit / (Loss) from ordinary activities before tax (3+4)**	**602.25**	**694.80**	**1,007.39**	**1,297.05**	**1,605.58**	**4,155.37**
6	Less: Tax Expenses:-						
	Current Tax	155.03	161.17	178.14	316.20	308.00	1,085.69
	Deferred Tax	37.03	28.38	(42.32)	65.41	(53.43)	(170.28)
7	**Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)**	**410.19**	**505.24**	**871.57**	**915.44**	**1,351.01**	**3,239.96**
8	Other Comprehensive Income (after tax)	(133.31)	500.21	(229.86)	366.90	63.64	(106.50)
9	**Total Comprehensive Income (after taxes) (7+8)**	**276.88**	**1,005.46**	**641.71**	**1,282.34**	**1,414.65**	**3,133.46**
10	Paid-Up equity share capital (Face Value Rs 10 per share)	**3,496.16**	**3,496.16**	**1,748.08**	**3,496.16**	**1,748.08**	**3,496.16**
11	Other Equity						**29,804.51**
12	**Earning per share (not annualised)**						
	(a) Basic	1.17	1.45	2.64	2.62	4.13	9.57
	(b) Diluted	1.17	1.45	2.64	2.62	4.13	9.57

Notes:

1. The above Unaudited Standalone Financial Results of the Company for the quarter and six months ended 30th September, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 6th November, 2026.
2. The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
3. Proposed Conversion of Debt and Divestment of Subsidiary

   The Company has approved the conversion of its entire outstanding debt, including service costs, aggregating up to ₹57.00 crore, extended to Kilitch Estro Biotech PLC ("KEB"), a material subsidiary incorporated in Ethiopia, into equity shares of KEB, subject to compliance with FEMA and other applicable laws.

   Further, the Company has approved the divestment of its entire shareholding in KEB, including additional shares arising from the aforesaid conversion, to HarmeeCare Pharmaceuticals, a state-owned public enterprise of the Oromia Regional State of Ethiopia, for an aggregate consideration of USD 14.00 million towards 100% shareholding and settlement of KEB's existing debts and liabilities, out of which USD 12.855 million shall be payable to the Company.

   The transaction is subject to applicable regulatory approvals and statutory compliances.
4. The figures for the corresponding previous periods have been reclassified/regrouped, wherever necessary, to make them comparable with the current periods.

C. SHARAT & ASSOCIATES Chintan Shah M. No. 127551 * 128593W *

For and on behalf of the Board of Directors

Mukund Mehta
Managing Director
DIN:- 00147876

KILITCH DRUGS (INDIA) LTD.

Place : Mumbai
Dated: 6th Nov, 2026

KILITCH DRUGS (INDIA) LIMITED

STANDALONE BALANCE SHEET AS AT 30TH SEPTEMBER 2026

CIN:L24239MH1992PLC066718

(Rs. In Lakhs)

Particulars	As at 30th Sept, 2026	As at 31st March, 2026
	Unaudited	Audited
ASSETS		
Non-current assets		
- Property, Plant and Equipment	17,068.14	1,927.12
- Capital work-in-progress	-	14,001.93
- Other Intangible Assets	25.75	26.41
Financial assets		
- Investments	7,830.92	7,189.06
- Loans/Advances	5,841.92	5,728.20
- Other Financial Assets	1.25	0.50
Deferred tax assets (Net)	392.52	457.93
(A)	**31,160.49**	**29,331.15**
Current Assets		
- Inventories	1,222.09	1,152.07
Financial assets		
- Investments	5,082.92	5,196.33
- Trade Receivables	11,231.32	11,724.43
- Cash & Cash Equivalents	398.38	929.63
- Other Bank Balances	121.52	100.20
- Other Financial Assets	1.80	3.25
Other Current Assets	1,676.90	1,508.48
(B)	**19,734.93**	**20,614.39**
TOTAL ASSETS (A + B)	**50,895.41**	**49,945.54**
EQUITY AND LIABILITIES		
Equity		
- Equity Share Capital	3,496.16	3,496.16
- Other Equity	31,086.83	29,804.51
(A)	**34,582.99**	**33,300.67**
Liabilities		
Non-Current liabilities		
Financial Liabilities		
- Borrowings	5,665.93	5,860.35
Provisions	67.94	67.94
(B)	**5,733.87**	**5,928.29**
Current liabilities		
Financial Liabilities		
- Borrowings	3,965.43	2,977.62
- Trade Payables		
Micro and Small Enterprises	-	-
Others	5,480.68	6,819.42
- Other Financial Liabilities	4.47	4.50
Provisions	295.98	221.87
Current Tax Liabilities [Net]	809.85	656.59
Other Current Liabilities	22.14	36.59
(C)	**10,578.55**	**10,716.59**
TOTAL EQUITY AND LIABILITIES (A+B+C)	**50,895.41**	**49,945.54**

C. SHARAT & ASSOCIATES Chintan Shah M. No. 127551 126693W

For and on behalf of the Board of Directors

Mukund Mehta
Managing Director
DIN:- 00147876

KILITCH DRUGS (INDIA) LTD.

Place : Mumbai
Dated: 6th Nov, 2026

KILITCH DRUGS (INDIA) LIMITED

UNAUDITED STANDALONE CASH FLOW STATEMENT FOR SIX MONTHS ENDED 30TH SEPTEMBER, 2026

CIN:L24239MH1992PLC066718

(Rs. in Lakhs)

Particulars	For the Six months ended 30th September, 2026		For Six Months Ended 30th September, 2025	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit / (Loss) before extraordinary items and tax		1,297.05		1,605.57
Adjustments for:				
Depreciation and amortization	420.30		102.57	
Interest income	(132.01)		(198.44)	
Dividend income	(3.01)		(1.32)	
(Profit)/Loss on sale of Investments	(166.21)		(367.73)	
Sundry Balances written back	(2.70)		6.10	
Provision for Gratuity & Leave Encashment	72.86		9.45	
Interest Expenses	202.43		126.52	
Expected Credit Loss	16.00		37.43	
Net unrealised exchange (gain) / loss	104.78	512.44	(289.40)	(574.82)
Operating profit / (loss) before working capital changes		**1,809.49**		**1,030.75**
Changes in working capital:				
Operating Assets:				
Inventories	(70.02)		229.93	
Trade receivables	375.03		(243.11)	
Other current assets	(168.42)		26.52	
Deposits & advances	13.77		(50.95)	
Other financial assets	1.45		1.78	
Operating Liabilities:				
Trade payables	(1,338.74)		(1,256.34)	
Other current liabilities	(14.48)		3.52	
Provisions	1.26	(1,200.15)	66.88	(1,221.77)
Gross cash flow from / (used in) operating activities		**609.34**		**(191.02)**
Direct Taxes (Paid) /refunded		(291.85)		(350.09)
Net cash flow from / (used in) operating activities (A)		**317.49**		**(541.11)**
B. CASH FLOW FROM INVESTING ACTIVITIES				
Purchases of Property, Plant & Equipment and CWIP	(1,558.73)		(5,150.32)	
Loans/Advances to related Parties	(127.48)		(190.35)	
Proceeds/(Purchases) (Net) of Current Investments	775.42		(7.23)	
Proceeds/(Purchases) (Net) of Non-Current Investments	(641.86)		(4.55)	
Movement in other Bank balances	(22.07)		6.03	
Interest received	132.01		198.44	
Dividend received	3.01		1.32	
		(1,439.70)		(5,146.66)
		(1,439.70)		(5,146.66)
Net cash flow from / (used in) investing activities (B)		**(1,439.70)**		**(5,146.66)**
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds From Right Issue of Equity Share Capital (incl. Share Premium-net of share issue expenses)	-		4,884.21	
Proceeds from Borrowings (Net of Repayments)	793.39		3,418.87	
Interest paid	(202.43)		(126.52)	
Net cash flow from / (used in) financing activities (C)		**590.96**		**8,176.56**
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		**(531.25)**		**2,488.77**
Cash and cash equivalents at the beginning		929.63		740.85
Cash and cash equivalents at the end		**398.38**		**3,229.62**
Cash and cash equivalents at the end *				
* Comprises:				
(a) Cash on hand		0.83		1.71
(b) Balances with banks				
(i) In current accounts		396.03		3,224.52
(ii) In earmarked accounts		1.52		3.39
		398.38		**3,229.62**

C. SHARAT & ASSOCIATES Chintan Shah M. No. 127551 * 126593W *

For and on behalf of the Board of Directors

Mukund Mehta
Managing Director
DIN:- 00147876

KILITCH DRUGS (INDIA) LTD.

Place : Mumbai
Dated: 6th Nov, 2026

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors of
Kilitch Drugs (India) Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Kilitch Drugs (India) Limited** (the 'Company') for the quarter and half year ended 30th September, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (the "Listing Regulations").

2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules thereafter and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, C. Sharat & Associates
Chartered Accountants
FRN: 128593W

Chintan Sharatchandra Shah
Digitally signed by Chintan Sharatchandra Shah
Date: 2026.11.06 19:53:30 +05'30'

C. SHARAT & ASSOCIATES
Chintan Shah
M. No. 127551
128593W

Chintan Sharatchandra Shah
Partner
Mem.No: 127551
UDIN No: 26127551ZWWKID9997
Place: Mumbai
Date:06/11/2026

KILITCH DRUGS (INDIA) LIMITED

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2026

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
Tel No: 022- 61214100. Email id: info@kilitch.com, Website: www.kilitch.com
CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

Sr. No.	Particulars	CONSOLIDATED					
		Three Months Ended			Six Months Ended		Year Ended
		30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income**						
	Net Sales/Income from Operations	5,021.50	4,487.89	4,892.45	9,509.39	9,206.42	23,547.49
	Other Income	215.90	289.69	666.04	505.59	921.77	1,123.86
	Total Income	**5,237.40**	**4,777.58**	**5,558.49**	**10,014.98**	**10,128.20**	**24,671.34**
2	**Expenses**						
	Cost of Materials Consumed	2,374.81	2,391.57	2,429.28	4,766.38	4,978.28	12,506.59
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(60.08)	(19.81)	206.90	(79.89)	130.81	106.73
	Employee Benefit Expenses	505.23	413.63	375.83	918.86	651.03	1,430.58
	Finance Cost	168.59	87.64	143.96	256.23	296.94	556.08
	Depreciation and Amortisation Expenses	382.19	109.33	86.28	491.52	170.60	362.31
	Export Product Registration/Commission	550.26	519.77	527.17	1,070.03	1,078.04	2,140.24
	Other expenses	983.08	889.16	849.16	1,872.24	1,537.71	3,703.38
	Total Expenses	**4,904.08**	**4,391.29**	**4,618.58**	**9,295.37**	**8,843.43**	**20,805.91**
3	**Profit before Exceptional items (1-2)**	**333.32**	**386.29**	**939.91**	**719.61**	**1,284.77**	**3,865.44**
4	Exceptional Items	-	-	-	-	-	-
5	**Profit from ordinary activities before tax (3+4)**	**333.32**	**386.29**	**939.91**	**719.61**	**1,284.77**	**3,865.44**
6	Less : Tax Expenses						
	Current Income Tax	155.03	161.17	178.14	316.20	308.00	1,085.69
	Deferred Tax	37.05	28.38	(42.23)	65.43	(53.44)	(170.28)
7	**Profit after tax for the period from continuing operations (5-6)**	**141.24**	**196.74**	**804.00**	**337.98**	**1,030.21**	**2,950.03**
8							
	Net Profit/(loss) After Tax & Share in Profits /(Loss) of Assocaites	141.24	196.74	804.00	337.98	1,030.21	2,950.03
9	Other Comprehensive Income (after Tax)	(133.31)	500.21	(229.86)	366.90	63.64	(106.50)
10	**Total Comprehensive Income (after taxes) (8+9)**	**7.93**	**696.95**	**574.14**	**704.88**	**1,093.85**	**2,843.53**
11	**Net Profit / (Loss) attributable to**						
	a) Owner of the Company	222.72	291.30	818.97	514.02	1,121.56	3,016.64
	b) Non Controlling Interest	(81.48)	(94.56)	(15.01)	(176.04)	(91.35)	(66.61)
12	**Other Comprehensive Income attributable to**						
	a) Owner of the Company	(133.31)	500.21	(229.86)	366.90	63.64	(106.50)
	b) Non Controlling Interest	-	-	-		-	-
13	**Total Income attributable to**						
	a) Owner of the Company	89.41	791.51	589.11	880.92	1,185.20	2,910.14
	b) Non Controlling Interest	(81.48)	(94.56)	(15.01)	(176.04)	(91.35)	(66.61)
14	**Paid-Up equity share capital (Face Value Rs. 10 per share)**	**3,496.16**	**3,496.16**	**1,748.08**	**3,496.16**	**1,748.08**	**3,496.16**
15	**Other Equity**						**24,469.17**
16	**Earning per share (not annualised)**						
	(a) Basic	0.64	0.83	2.49	1.47	3.43	8.91
	(b) Diluted	0.64	0.83	2.49	1.47	3.43	8.91

Notes:

1. The above unaudited Consolidated Financial Results of the Company for the quarter and six months ended 30th September, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 6th November, 2026.

2. The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.

3. Proposed Conversion of Debt and Divestment of Subsidiary
The Company has approved the conversion of its entire outstanding debt, including service costs, aggregating up to ₹57.00 crore, extended to Kilitch Estro Biotech PLC ("KEB"), a material subsidiary incorporated in Ethiopia, into equity shares of KEB, subject to compliance with FEMA and other applicable laws.
Further, the Company has approved the divestment of its entire shareholding in KEB, including additional shares arising from the aforesaid conversion, to HarmeeCare Pharmaceuticals, a state-owned public enterprise of the Oromia Regional State of Ethiopia, for an aggregate consideration of USD 14.00 million towards 100% shareholding and settlement of KEB's existing debts and liabilities, out of which USD 12.855 million shall be payable to the Company.
The transaction is subject to applicable regulatory approvals and statutory compliances.

4. The figures for the corresponding previous periods have been reclassified/rearranged, wherever necessary, to make them comparable with the current periods.

For and on behalf of the Board of Directors

Mukund P. Mehta
Director
DIN:- 00147876

Place: Mumbai
Date: 6th November, 2026

SHARAT & ASSOCIATES Chintan Shah M. No. 127561 128593W

KILITCH DRUGS (INDIA) LTD.

KILITCH DRUGS (INDIA) LIMITED

UNAUDITED CONSOLIDATED BALANCE SHEET AS AT 30TH SEPTEMBER, 2026

CIN:L24239MH1992PLC066718

(Rs. In Lakhs)

Particulars	As at 30th September, 2026	As at 31st March, 2026
ASSETS		
Non-current assets		
Property, plant and Equipment	20,239.06	4,869.58
Capital work-in-progress	-	14,001.93
Other Intangible assets	25.75	26.41
Goodwill on Merger	1,727.22	1,769.34
Financial assets		
- Investments	2,930.01	2,288.15
- Loans/Advances	127.83	141.29
- Other Financials Assets	1.25	0.50
Deferred tax assets (Net)	392.79	458.21
(A)	**25,443.91**	**23,555.41**
Current assets		
Inventories	1,222.09	1,152.07
Financial assets		
- Investments	5,082.92	5,196.33
- Trade and other receivables	11,382.20	12,017.71
- Cash and cash equivalents	569.08	1,577.40
- Other Bank Balances	121.52	100.20
- Other Financials Assets	1.80	3.25
Other current assets	2,606.82	2,172.55
(B)	**20,986.43**	**22,219.51**
TOTAL ASSETS (A + B)	**46,430.34**	**45,774.92**
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	3,496.16	3,496.16
Other Equity	25,358.42	24,469.17
Equity attributable to the owners	**28,854.58**	**27,965.33**
Non-controlling interest	(450.55)	(278.62)
(A)	**28,404.03**	**27,686.71**
Liabilities		
Non-current liabilities		
Financial liabilities		
- Borrowings	5,665.93	5,860.35
Provisions	67.94	67.94
(B)	**5,733.87**	**5,928.29**
Current liabilities		
Financial liabilities		
- Borrowings	3,998.36	3,010.55
- Trade Payables		
Micro and Small Enterprises	-	-
Others	6,899.45	7,964.65
- Other financial liabilities	4.47	4.50
Provisions	296.34	222.23
Current tax Liabilities (Net)	809.85	656.59
Other current liabilities	283.97	301.40
(C)	**12,292.44**	**12,159.92**
TOTAL EQUITY AND LIABILITIES (A + B +C)	**46,430.34**	**45,774.92**

SHARAT & ASSOCIATES Chintan Shah M. No. 127551 126592W

For and on behalf of the Board of Directors

Mukund P. Mehta
Managing Director
DIN:- 00147876

KILITCH DRUGS (INDIA) LTD.

Place : Mumbai
Date : 6th November, 2026

KILITCH DRUGS (INDIA) LIMITED

UNAUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE SIX MONTHS ENDED ON 30TH SEPTEMBER, 2026

CIN:L24239MH1992PLC066718

(Rs. In Lakhs)

Particulars	For the Six Months ended 30th September, 2026		For the Six Months ended 30th September, 2025	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit / (Loss) before extraordinary items and tax		**719.61**		**1,284.78**
Adjustments for:				
Depreciation and amortisation	491.52		170.60	
Interest income	(6.15)		(9.76)	
Dividend income	(3.01)		(1.32)	
(Profit)/Loss on sale of Investments	(166.21)		(367.73)	
Sundry Balances written back	(2.70)		6.10	
Provision for Gratuity & Leave Encashment	72.86		9.45	
Interest Expenses	256.23		296.94	
Expected Credit Loss	16.00		37.43	
Net unrealised exchange (gain) / loss	104.78	763.32	(289.40)	(147.69)
Operating profit / (loss) before working capital changes		**1,482.93**		**1,137.09**
Changes in working capital:				
Operating Assets:				
Inventories	(70.02)		229.93	
Trade receivables	517.43		(571.23)	
Other financial Assets	1.45		-	
Other current assets	(434.27)		(192.68)	
Deposit & Advances	13.47		(9.79)	
Operating Liabilities:				
Trade payables	(1,065.20)		(976.96)	
Other financial liabilities	(0.03)		(0.51)	
Other current liabilities	(17.42)		4.03	
Short-term provisions	1.26	(1,053.33)	68.20	(1,449.02)
Gross cash flow from / (used in) operating activities		429.60		(311.93)
Direct Taxes (Paid) / refunded		(291.85)		(350.09)
Net cash flow from / (used in) operating activities		**137.75**		**(662.02)**
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on PPE,CWIP including capital advances	(1,807.99)		(5,150.31)	
Proceeds (Net) from the sale of Current investments	775.42		(7.18)	
(Purchase)/Sale (Net) of long-term investments:	(641.86)		(4.55)	
Movement in other Bank balance	(22.07)		6.03	
Interest received	6.15		9.76	
Dividend received	3.01		1.32	
		(1,687.34)		(5,144.93)
Net cash flow from / (used in) investing activities (B)		**(1,687.34)**		**(5,144.93)**
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds From Right Issue of Equity Share Capital (incl. Share Premium- net of share issue expenses)	-		4,884.21	
Proceeds from Borrowings (Net of Repayments)	793.39		3,418.88	
Proceeds from Minorities	4.11		129.80	
Interest paid	(256.23)		(296.94)	
		541.27		8,135.95
Net cash flow from / (used in) financing activities (C)		**541.27**		**8,135.95**
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		**(1,008.32)**		**2,329.00**
Cash and cash equivalents at the beginning of the year		1,577.40		980.05
Cash and cash equivalents at the end of the Period		**569.08**		**3,309.05**
Cash and cash equivalents at the end of the Period *				
* Comprises:				
(a) Cash on hand		0.83		1.71
(b) Balances with banks				
(i) In current accounts		566.73		3,303.95
(ii) In earmarked accounts		1.52		3.39
		569.08		**3,309.05**

C. SHARAT & ASSOCIATES
Chintan Shah
M. No. 127551
Z2008390N

For and on behalf of the Board of Directors

Mukund P. Mehta
Managing Director
DIN:- 00147876

KILITCH DRUGS (INDIA) LTD.

Place : Mumbai
Date : 6th November, 2026

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors of
Kilitch Drugs (India) Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Kilitch Drugs (india) Limited** ("the Parent"), and its' subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended 30th September, 2026 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, to the extent applicable.

4. The Statement includes the results of entities as given below:

   List of Subsidiaries:
   1. Monarchy Healthserve Private Limited
   2. Kilitch Estro Biotech PLC – Foreign Subsidiary

5. (a) We did not review the interim financial results and other financial information in respect of one subsidiary whose interim financial results/information reflects, total assets of Rs. 1,730.62 Lakhs, total revenues of Rs. Nil and Rs. Nil, total net profit/(loss) after tax of Rs. (22.17) Lakhs and Rs. (44.01) Lakhs and total comprehensive income/(loss) of Rs. (22.17) Lakhs and Rs. (44.01) Lakhs for the quarter ended 30th September, 2026 and for the period from 1st April, 2026 to 30th September, 2026, respectively and net cash flow of Rs. Nil for the period from 1st April, 2026 to 30th September, 2026. These interim financial results and other financial information have been reviewed by other auditors, whose reports have been furnished to us by the management of the Company and our conclusion in so far as it relates to the affairs of such subsidiary is based solely on the report of other auditors.

(b)The Statement includes interim financial results and other financial information in respect of one foreign subsidiary which reflects ,total assets of Rs. 5,973.47 Lakhs, total revenues of Rs. 672.24 Lakhs and Rs. 1,068.93 Lakhs, total net profit/(loss) after tax of Rs. (246.90) Lakhs and Rs. (533.44) Lakhs and total comprehensive income/(loss) of Rs. (246.90) Lakhs and Rs. (533.44) Lakhs for the quarter ended 30th September, 2026 and for the period from 1st April, 2026 to 30th September, 2026, respectively and net cash outflow of Rs. 477.06 Lakhs for the period from 1st April, 2026 to 30th September, 2026 as considered in the consolidated financial results. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of this subsidiary is solely based on such unaudited financial statements as certified by the management.

Our conclusion on the Statement is not modified in respect of the above matter.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on management certified financial statements referred in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, C. Sharat & Associates
Chartered Accountants
FRN: 128593W



Chintan Sharatchandra Shah
Digitally signed by Chintan Sharatchandra Shah
Date: 2026.11.06 20:00:33 +05'30'

Chintan Sharatchandra Shah
Partner
Mem.No: 127551
UDIN No: 26127551ZVNSYS6554
Place: Mumbai
Date:06/11/2026